SERAGEN INC
8-K, 1996-07-01
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: PROSPECT STREET HIGH INCOME PORTFOLIO INC, NSAR-A, 1996-07-01
Next: BURLINGTON RESOURCES INC, 11-K, 1996-07-01



<PAGE>   1
                                 UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549


                               ------------------


                                    FORM 8-K

                                 CURRENT REPORT

                         PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934


                               ------------------



         Date of Report (Date of earliest event reported): JULY 1, 1996
                                                           ------------


                                  SERAGEN, INC.
                                  -------------
             (Exact name of registrant as specified in its charter)


        DELAWARE                    0-19855                  04-2662345
        --------                    -------                  ----------
     (State or other              (Commission              (IRS Employer
     jurisdiction of              File Number)           Identification No.
     incorporation)


                 97 SOUTH STREET, HOPKINTON, MASSACHUSETTS 01748
                 -----------------------------------------------
               (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code; (508) 435-2331

                                Page 1 of 6 pages
                             Exhibit Index on page 4
<PAGE>   2

ITEM 5. OTHER EVENTS.
- ------- -------------

        The Registrant's pro forma balance sheet as of May 31, 1996 and the
statement of operations for the five month period ended May 31, 1996, filed as
Exhibit 99.1 hereto, demonstrate the Registrant's compliance as of May 31, 1996
on a pro forma basis with the net tangible asset requirement for continued
inclusion on the Nasdaq National Market. The information contained in Exhibit
99.1 is incorporated herein by reference.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
- ------- ----------------------------------

(c)     Exhibit.

        99.1   The Registrant's Pro Forma Balance Sheet as of May 31, 1996 and
               Statement of Operations for the five month period ending May 31,
               1996.


                                       2
<PAGE>   3





                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        Seragen, Inc.
                                        -------------
                                        (Registrant)


   Date:  July 1, 1996                  /s/ Thomas N. Konatich
                                        ----------------------
                                        Thomas N. Konatich
                                        Vice President for Finance


                                       3
<PAGE>   4




<TABLE>
                                  EXHIBIT INDEX
                                  -------------
<CAPTION>

Exhibit                                                  Sequential
Number             Description                           Page Number
- ------             -----------                           -----------

<S>                <C>                                        <C>
99.1               The Registrant's Pro Forma Balance         5
                   Sheet as of May 31, 1996 and
                   Statement of Operations for the five
                   month period ending May 31, 1996
</TABLE>



                                       4

<PAGE>   1
                                                                    Exhibit 99.1
                                                                             -5-


                            SERAGEN,INC.
<TABLE>
                            BALANCE SHEET AND PRO FORMA BALANCE SHEET
                                     (DOLLARS IN THOUSANDS)
                                           (UNAUDITED)
<CAPTION>

                                                                                    Pro Forma
                                                        May 31, 1996  Adjustments  May 31, 1996
                                                        ------------  -----------  ------------
<S>                                                        <C>          <C>         <C>      
                  ASSETS
Current assets:
    Cash & cash equivalents                                $   4,758    $  2,300    $   7,058
    Restricted cash                                              435                      435 
    Contract receivable                                          688                      688 
    Unbilled contract receivable                                 828                      828 
    Prepaid expenses and other current assets                    269                      269 
                                                           ---------    --------    ---------

         Total current assets                                  6,978       2,300        9,278

Property and equipment, net                                    5,100                    5,100

Investment in affiliate                                        1,430                    1,430
Prepaid interest                                               3,095      (3,095)           0
Other assets                                                     517        (424)          93
                                                           ---------    --------    ---------
                                                           $  17,120   ($  1,219)   $  15,901
                                                           =========    ========    =========

LIABILITIES & STOCKHOLDER'S (DEFICIT) EQUITY

Current liabilities:
    Accounts payable                                             895                      895
    Current maturities of long-term debt                         195                      195
    Accrued commission payable                                   300                      300
    Accrued expenses                                           2,576                    2,576
                                                           ---------    --------    ---------

         Total current liabilities                             3,966                    3,966

Non-current liabilities:
    Long-term debt, less current maturities                   21,500     (21,500)           0
    Long-term obligation, less unamortized discount            3,727                    3,727
    Affiliate guarantee                                        2,076                    2,076
                                                           ---------    --------    ---------

         Total non-current liabilities                        27,303     (21,500)       5,803

Commitments and contingencies
Stockholders' (deficit) equity:
    Common & preferred stock $.01 par value                      166                      166
    Additional paid-in capital                               145,577      23,800      169,377
    Accumulated deficit                                     (159,825)     (3,519)    (163,344)
                                                           ---------    --------    ---------
                                                             (14,082)     20,281        6,199

    Less treasury stock                                          (67)                     (67)
                                                           ---------    --------    ---------
           Total stockholders' (deficit) equity              (14,149)     20,281        6,132
                                                           ---------    --------    ---------

    Total liabilities and stockholders' (deficit) equity   $  17,120   ($  1,219)   $  15,901
                                                           =========    ========    =========
<FN>


Note:        The Pro Forma Balance Sheet as of May 31, 1996 reflects a transaction completed on
             July 1, 1996. In this transaction, the Company borrowed the remaining loan amounts
             under its $23.8 million lines of credit, and restructured its arrangement with the
             guarantors of this financing to release the Company from its liability to the banks
             involved. The lines of credit have been replaced with preferred stock convertible
             into common stock. The investors have also received common stock purchase warrants.
             The adjustments include a write-off of the costs of the previous bank financing and
             amortization of warrants issued in connection with the bank financing.

</TABLE>



<PAGE>   2

                                                                             -6-


                             SERAGEN,INC.
<TABLE>
                          INCOME STATEMENT AND PRO FORMA INCOME STATEMENT
                                       (DOLLARS IN THOUSANDS)
                                            (UNAUDITED)
<CAPTION>

                                                                 
                                                                                        Pro Forma  
                                                     For the five                      for the five
                                                     months ended                      months ended
                                                     May 31, 1996      Adjustments     May 31,1996 
                                                     ------------      -----------     ----------- 

<S>                                                     <C>              <C>             <C>      
Revenue
   Contract revenue and license fees                    $ 7,371                          $  7,371
Operating expenses;                                                                              
   Cost of contract revenue                               2,271                             2,271
   Research and development                               5,960                             5,960
   General and administrative                             4,201              424            4,625
                                                        -------          -------         --------
                                                         12,432              424           12,856
                                                        -------          -------         --------
          Loss from operations                           (5,061)            (424)          (5,485)

Equity in loss of affiliate                               1,170                             1,170
Interest income                                              29                                29
Interest expense                                          1,350            3,095            4,445
                                                        -------          -------         --------

         Net loss                                      ($ 7,552)         ($3,519)        ($11,071)
                                                        =======          =======         ========
</TABLE>







© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission